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ABSTRACT
Establishment of the stable provirus is an essential
step in retroviral replication, orchestrated by inte-
grase (IN), a virus-derived enzyme. Until now, avail-
able structural information was limited to the INs of
human immunodeficiency virus type 1 (HIV-1), avian
sarcoma virus (ASV) and their close orthologs from
the Lentivirus and Alpharetrovirus genera. Here, we
characterized the in vitro activity of the prototype
foamy virus (PFV) IN from the Spumavirus genus
and determined the three-dimensional structure of
its catalytic core domain (CCD). Recombinant PFV
IN displayed robust and almost exclusively con-
certed integration activity in vitro utilizing donor
DNA substrates as short as 16bp, underscoring its
significance as a model for detailed structural stu-
dies. Comparison of the HIV-1, ASV and PFV CCD
structures highlighted both conserved as well as
unique structural features such as organization of
the active site and the putative host factor binding
face. Despite possessing very limited sequence
identity to its HIV counterpart, PFV IN was sensitive
to HIV IN strand transfer inhibitors, suggesting that
this class of inhibitors target the most conserved
features of retroviral IN-DNA complexes.
INTRODUCTION
Upon entry into a target cell, a retrovirus undergoes
reverse transcription to convert its diploid positive-
strand RNA genome into a linear double-stranded
cDNA molecule. Integration of the cDNA into the host
cell genome is orchestrated by IN (1–3). This virus-derived
enzyme engages both termini of the cDNA molecule-
recognizing attachment (att) sites located at the ends of
long terminal repeats (LTRs) to carry out two reactions:
(i)3 0-processing, a single-strand endonucleolytic reaction
that exposes 30-OH groups of the invariant CA dinucleo-
tides, and (ii) strand transfer that inserts the 30-termini of
the viral cDNA into the chromosomal DNA. The CA
dinucleotides found in the immediate vicinity of the
30-ends of cDNA from all retroviruses and LTR-
retrotransposons are essential for IN function (4). Most
commonly, two or three nucleotides are removed from
both 30-termini of retroviral cDNA during 30-processing.
Because in Spumavirus the polypurine tract (PPT) directly
abuts the U3 sequence, reverse transcription does not
add additional nucleotides to the U3 (left) end of the
cDNA, and, as a consequence, only the right (U5) end is
processed (5,6).
Based on structural and mechanistic similarities, retro-
viral INs belong to a diverse superfamily of metal-depen-
dent nucleotidyl strand transferases, which notably
includes ribonuclease (RNase) H enzymes and prokaryotic
transposases (7). The catalytic mechanism of the RNase H
superfamily of enzymes has been elucidated by a series of
detailed crystal structures (8,9). Generally, reactions cata-
lyzed by nucleotidyl transferases proceed via SN2 nucleo-
philic substitution at the phosphorus atom of the scissile
phosphodiester bond. Unlike tyrosine or serine recombi-
nases, retroviral INs and transposases use a water mole-
cule as nucleophile during endonucleolysis, and the 30-OH
group of the viral cDNA during strand transfer. The
active sites of these enzymes contain three or four essential
acidic residues that participate in coordination of a pair of
Mg
2+ or Mn
2+ cations. The tightly coordinated metal
cations act as Lewis acids, one serving to position the
incoming nucleophile (water or a 30-OH group) and the
other to activate the leaving 30-OH group, both stabilizing
the hypothetical pentacovalent phosphorus intermediate
(10). An elegant ‘ping-pong’ mechanism wherein the
roles of the metal cations switch between catalytic cycles
(30-processing and strand transfer in case of retroviral INs)
Present address:
Eugene Valkov, School of Molecular and Microbial Sciences, University of Queensland, Brisbane, Australia
*To whom correspondence should be addressed. Tel: +44 20 75943655; Fax: +44 20 75943906; Email: p.cherepanov@imperial.ac.uk
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.has been proposed by Yang and colleagues (8). In retro-
viral IN, a pair of Asp and a Glu residue comprise the
catalytic D,DX35E motif (11). Reported eﬀorts to crystal-
lize HIV-1 or ASV INs in a Mg
2+-bound form have so far
resulted in structures with a single Mg
2+ cation coordi-
nated by the Asp residues (12–14), although a pair of
metal cations is expected to be present during catalysis
(8,15).
Retroviral INs share a common three-domain organiza-
tion: the catalytic core domain (CCD) ﬂanked by smaller
N- and C-terminal domains (NTD and CTD). The NTD
is a compact three-helical bundle stabilized by a Zn
2+
cation, coordinated via His and Cys residues of the invar-
iant HHCC motif (16,17). Comprised solely of b-strands,
the SH3-like CTD is rich in Lys and Arg residues and has
nonspeciﬁc DNA-binding activity (18–21). The architec-
ture of the functional IN–DNA complex and the precise
roles of the NTD and the CTD are yet to be elucidated.
Although the basic mechanism of phosphodiester bond
cleavage and joining by the RNase H superfamily of
enzymes is relatively well understood, structural informa-
tion detailing catalysis by retroviral INs would be invalu-
able for antiretroviral drug development.
Productive integration requires insertion of both cDNA
ends into chromosomal DNA. In the process, referred to
as concerted or full-site integration, a pair of strand trans-
fer events take place across the major groove in target
DNA. As a result, the integrated viral cDNA is initially
ﬂanked by short single-stranded gaps, which have to be
repaired to produce short duplications of the target DNA
sequence. The duplication size is genus-speciﬁc and equals
4bp for Spumavirus (5). Although the enzymatic activities
of retroviral INs can be readily observed in vitro, con-
certed integration typically requires laborious optimiza-
tions of reaction conditions, the predominant strand
transfer product often being uncoupled single-end (half-
site) integration (22–25). Interestingly, side-by-side com-
parison of three lentiviral INs revealed that the propensity
of INs to carry out concerted integration in vitro is
enzyme-speciﬁc (26), suggesting that synaptic complex
assembly might generally require a protein co-factor(s).
Retroviral integration is not entirely random, and
genus-speciﬁc biases on the level of local target DNA
sequence and genomic scales have been reported (27).
HIV-1 and other members of Lentivirus strongly favor
integration within active transcription units, whereas
Moloney murine leukemia virus (MoMLV), a
Gammaretrovirus, preferentially integrates in the vicinity
of transcription start sites and CpG islands (28–34). Less
distinctive patterns were observed for other genera. The
prototype foamy virus (PFV), a member of Spumavirus,
slightly disfavors integration within transcription units,
displaying only a weak correlation with local gene expres-
sion activity (35,36). Integration site selection of Lentivirus
was shown to depend on LEDGF/p75 (37). This chroma-
tin-associated host protein interacts directly with lentiviral
INs (38–40) and is required for eﬃcient HIV–1 replication
(41–43). In addition to aﬀecting the levels of HIV-1 inte-
gration, ablation of LEDGF/p75 expression in target cells
grossly aﬀected the distribution of the residual integration
sites (43–45). Given that even the distant relatives of
retroviruses, yeast LTR-retrotransposons, target their
integration via direct interaction between their INs and
chromatin-associated host factors (46,47), it seems unli-
kely that this mechanism would not be conserved through-
out the Retroviridae family. Even though non-lentiviral
targeting factors have yet to be identiﬁed, based on the
Lentivirus-LEDGF/p75 paradigm, they can be predicted
to be genus-speciﬁc and to engage the CCDs of their cog-
nate INs (40). Although Lentivirus, which notably includes
human immunodeﬁciency viruses (HIV–1 and -2), is the
most clinically relevant genus, comparative analyses of
divergent retroviral INs will be essential to uncover con-
served as well as genus-speciﬁc aspects of retroviral DNA
integration. Furthermore, nonlentiviral INs can provide
convenient model systems for structural studies of retro-
viral integration. In this study we describe the in vitro
enzymatic properties of a spumaviral IN and present a
detailed three-dimensional structure of its CCD.
MATERIALS AND METHODS
DNA
Oligonucleotides used in this work were: PC179,
50-GAGCCCCGGG AAAGGATATCCCAAACAATA
TAC; PC180, 50-GCGCGGATCCTCATTCATTT TTT
TCCAAATGATCCATTG; PC192, 50-GGCGGGTACC
AGAAAGCAGGTA GCTTGCAGTGG; PC193, 50-GG
CGGGTACCCGAAGAACTCCAGCATG AGATCC;
PC370, 50-GTAAAAGGATTTGTATATTAGC; PC371,
50-CCCATTGA CGCAAATGGGCGGTAG; PC376,
50-GAGCCCCGGGTCATCTGG TCCTATTCT AAG
ACCAGATAG; PC377, 50-GCGTGGATCCTCAGGTG
GATGGATGGTATA AAGAAGTAC; PC401, 50-TAC
TTTGCAGGGCTTCCCAACC; PC402, 50-CGAAATG
ACCGACCAAGCGACG; PC503, 50-GAGCCCCGGG
TGT AATACCAAAAAACCAAACCTGGATG, EV53,
50-AGGATAATCAATATA CAAAATTCCATGACA
AT; EV54, 50-ATTGTCATGGAATTTTGTATATTGA
TTATCCT; EV55, 50-AGGATAATCAATATACAAAA
TTCCATGACA; EV57, 50-TAATCAATATACAAAAT
TCCATGACA; EV58, 50-ATTGTCATGGAATTT TGT
ATATTG ATTA; EV59, 50-CAATATACAAAATTCC
ATGACA; EV60, 50-ATTGTCATG GAATTTTGTAT
ATTG; EV61, 50-TATACAAAATTCCATGACA; EV62,
50-ATTGTCATGGAATTTTGTATA; EV63, 50-ATACA
AAATTCCA TGACA; EV64, 50-ATTGTCATGGAA
TTTTGTAT; EV65, 50-TACAAAATTC CATGACA;
EV66, 50-ATTGTCATGGAATTTTGTA; EV67, 50-ACA
AAA TTCCATGACA; EV68, 50-ATTGTCATGGAAT
TTTGT; EV79, 50-AAAATTCCAT GACA; EV80,
50-ATTGTCATGGAATTTT; EV81, 50-AAATTCCATG
ACA; EV82, 50-ATTGTCATGGAATTT; EV85, 50-CAA
AATTCCATGACA; EV86, 50-ATTGT CATGGAAT
TTTG.
To make pCPH6P-HSRV2-IN, pSSH6P-HSRF2-
INFL, and pCPH6P-HSRV2-INCCD, DNA fragments
PCR-ampliﬁed using Pfu DNA polymerase (Stratagene),
pcHSRV2 (48) template and primer pairs PC179/PC180,
PC503/PC180 or PC376/PC377, respectively, were
digested with XmaI and BamHI and ligated between
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of the BIV IN coding sequence.
Production of PFV INfor enzymatic assays
To prepare PFV IN (IN residues 22–392, corresponding
to PFV POL 773–1143) or full-length PFV IN (IN 1-392,
POL 752–1143), Escherichia coli PC2 cells [BL21(DE3),
endA::Tet
R,T 1
R, pLysS] (26) transformed with
pCPH6P-HSRV2-IN or pSSH6P-HSRV2-INFL, respec-
tively, were grown in Lennox LB broth in shake ﬂasks at
298Ct oa nA 600 of 0.9–1.0 prior to addition of 0.25mM
isopropyl-b-D-thiogalactopyranoside (IPTG) and 50mM
ZnCl2. Following a 4-h induction at 258C, bacteria were
harvested and stored at –708C. For puriﬁcation, thawed
bacterial paste was sonicated in HSB (0.5M NaCl, 50mM
Tris–HCl, pH 7.4) in the presence of 0.5mM phenylmeth-
lysulfonyl ﬂuoride (PMSF). The lysate, precleared by cen-
trifugation at 20000g for 45min and supplemented with
20mM imidazole (pH 7.5), was incubated with Ni–NTA
agarose (Qiagen) at 48C for 30min. The resin was exten-
sively washed in HSB containing 20mM imidazole and
bound proteins were eluted with 200mM imidazole in
HSB and supplemented with 10mM 1,4-dithiothreitol
(DTT). Following removal of the hexahistidine tag by
overnight digestion with human rhinovirus 14 (HRV14)
3C protease (49) at 78C, the protein was diluted with 4
vol of ice-cold 50mM Tris–HCl, pH 7.4 and loaded onto
a 5-ml HiTrap heparin column (GE Healthcare). The IN
proteins eluted with a linear gradient of 0.2–1.0M NaCl in
50mM Tris–HCl, pH 7.4 were further puriﬁed by gel ﬁl-
tration chromatography on a HiLoad 16/60 Superdex-200
column (GE Healthcare) in 200mM NaCl, 50mM Tris–
HCl, pH 7.4, concentrated to 5–12mg/ml, supplemented
with 10mM DTT and 10% (v/v) glycerol, ﬂash-frozen in
liquid nitrogen and stored at  708C. Protein concentration
was determined using the Bradford assay (Bio-Rad
Laboratories) with a BSA standard. Where indicated,
molar concentrations refer to the monomer protein forms.
In vitro PFVIN assays andsequence analysis of
integration products
Short (32–15bp) donor DNA substrates were obtained by
annealing pairs of HPLC-puriﬁed synthetic oligonucleo-
tides (VH Bio, UK). Blunt-ended 32bp U5 donor was
prepared using EV53 and EV54; preprocessed donors:
32bp, EV55 and EV54; 28bp, EV57 and EV58; 24bp,
EV59 and EV60; 21bp, EV61 and EV62; 20bp, EV63
and EV64; 19bp, EV65 and EV66; 18bp, EV67 and
EV68; 17bp, EV85 and EV86; 16bp, EV79 and EV80;
15bp, EV81 and EV82. 120-bp and 420-bp, donor DNA
substrates were obtained as PCR products using Pfu DNA
polymerase, pcHSRV2 template with primer pairs PC370/
EV54 and PC371/EV54, respectively. The resulting PCR
fragments were puriﬁed by electrophoresis through 2%
(w/v) agarose and isolated using QIAquick gel extraction
kit (Qiagen).
A standard strand transfer reaction contained 1.5mM
PFV IN or full-length IN, 0.75mM donor oligonucleo-
tide DNA substrate, 4nM (300ng) supercoiled pGEM9-
Zf(–) target DNA (referred to as pGEM), 125mM NaCl,
5mM MgSO4,4mM ZnCl2, 10mM DTT, 25mM Bis–Tris
propane, pH 7.45 in a ﬁnal volume of 40ml. Conditions
were modiﬁed as indicated in the ‘Results’ section.
Reactions were initiated by addition of IN diluted in
150mM NaCl, 2mM DTT, 10mM Tris–HCl, pH 7.4
and, following incubation at 378C for 90min, were
stopped by addition of 0.5% (w/v) SDS and 25mM
EDTA. Reaction products, deproteinized by digestion
with 20mg proteinase K for 30min at 378C and precipita-
tion with ethanol, were separated in 1.5% agarose gels and
visualized by staining with ethidium bromide.
For sequence analysis, concerted integration products
isolated from agarose gels were treated with phage 29
DNA polymerase (New England Biolabs) in the presence
of 500mM dNTPs, 50-phosphorylated using phage T4
polynucleotide kinase (New England Biolabs) and ligated
to a blunt-ended linear DNA fragment encoding Tn5 ami-
noglycoside-30-O-phosphotransferase (kanamycin resis-
tance) gene. The Kan
R cassette, ﬂanked by KpnI sites,
was obtained as a PCR product using Pfu DNA polymer-
ase with primers PC192/PC193 and pCP15 template
(26,50). Escherichia coli XLI-Blue cells, transformed with
the ligation products, were selected with 35mg/ml kana-
mycin. Plasmids isolated from individual colonies that
released the expected  1.1 and 3-kb fragments upon
digestion with KpnI were sequenced using primers
PC401 and PC402, which anneal within the Kan
R cassette.
Virus preparation and infections
Human embryonic kidney cells 293T and canine osteosar-
coma D17 cells were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 2mM L-glutamine at 378Ci n5 %
CO2 humidiﬁed atmosphere. The PFV-derived retro-
viral vector -EGFP expressing enhanced green ﬂuor-
escent protein (EGFP) was prepared by co-transfection of
293T cells with p-SFFV-EGFP (Patton,G.S. and
McClure,M., unpublished data), pCiPS, pCiSc, and
pCiES (51). Cell culture supernatants were passed through
0.45-mm nitrocellulose ﬁlters (Millipore), and the virus
concentrated by ultracentifugation was stored in liquid
nitrogen. D17 cells seeded in 96-well plates (50000 cells
per well) were infected with -EGFP diluted in DMEM,
10% FCS in the presence of strand transfer inhibitors and/
or 0.65% DMSO. To increase transduction eﬃciency, the
virus-cell mixtures were subjected to centrifugation for 3h
at 1000g at room temperature. Cytotoxicity was observed
when GS9137 and MK0518 when used at concentrations
exceeding 10 and 100mM, respectively. Two days postin-
fection cells were transferred into 24-well plates and were
harvested for analysis 5 days postinfection. The percen-
tage of EGFP
+ cells and their mean ﬂuorescence intensity
(MFI) were determined by ﬂuorescence activated cell sort-
ing (FACS) on a CyAn ADP instrument (DAKO
Cytomation). Infection in the absence of strand transfer
inhibitors resulted in 49 5% of EGFP
+ D17 cells; the
EGFP
+ population was reduced to 27 4% and 16 4%
in the presence of the highest concentration of GS1930
and MK0518, respectively, with a concomitant reduction
of the MFI. The percentage of EGFP
+ cells times MFI of
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+ cell population was used to generate relative
infectivity data. Mean values and standard deviations
were determined based on results of triplicate infections.
Crystallization and structure determination of
thePFV INCCD
A selenomethionine (SeMet) derivative of the IN CCD
(corresponding to residues 860–1058 of PFV POL) was
produced in E. coli B834 cells (Novagen) transformed
with pCPH6P-HSRV2-INCCD. Bacteria were grown in
Athena minimal medium (AthenaES, Baltimore, MD)
supplemented with 120mg/ml ampicillin, 34mg/ml chlor-
amphenicol, and 40mg/ml SeMet (Molecular
Dimensions) to an A600 of 0.5, and protein expression
was induced with 0.25mM IPTG for 5h at 258C. Cells
were sonicated in 0.5M NaCl, 1mM DTT, 0.5mM
PMSF, 50mM HEPES-NaOH, pH 8.0. Precleared lysate
supplemented with 50mM imidazole was injected into a
5-ml His-Trap FF column (GE Healthcare), and bound
protein was eluted with a linear 50–500mM gradient of
imidazole in 0.5M NaCl, 1mM DTT, 50mM HEPES-
NaOH, pH 8.0. The hexahistidine tag was removed by
digestion with HRV14 3C protease and the protein was
further puriﬁed by gel ﬁltration through a HiLoad 16/60
Superdex-200 column in 0.2M NaCl, 1mM DTT, 20mM
Tris–HCl, pH 7.5. Crystals of SeMet-derivatized PFV IN
CCD were obtained in hanging drops at 188C by mixing
2ml protein (1.8mg/ml) and 2ml reservoir solution con-
taining 1.0M ammonium formate, 0.2M MgCl2,5 m M
DTT and 0.1M MES-NaOH, pH 6.5. The crystals were
cryoprotected in reservoir solution supplemented with
20% (v/v) glycerol for several seconds and were then
frozen in liquid nitrogen by rapid immersion.
Diﬀraction data from the SeMet-derivatized PFV IN
CCD crystals were collected on beamline BM14at the
European Synchrotron Radiation Facility (Grenoble,
France) and processed using MOSFLM (52) and
SCALA (53). Analysis of integrated data using
POINTLESS (54) indicated that the crystals belong to
space group P6122 or P6522. Solvent content analysis sug-
gested a single protein chain per asymmetric unit (solvent
content of 41%). Initial attempts to determine the struc-
ture by molecular replacement (MR) in PHASER (55)
using search models based on HIV-1 or ASV IN CCD
structures (7,13,56) and a native 2.5-A ˚ data set, resulted
in a plausible solution in space group P6122. Although
signiﬁcant model bias did not allow reﬁnement of the
structure, the MR solution reproduced the expected
dimeric CCD arrangement via a 2-fold crystallographic
symmetry axis with good overall crystal packing. The
MR phases were utilized in the calculation of an anoma-
lous Fourier map using the SeMet data set collected at the
Se absorption peak ( =0.97837A ˚ ) and a 8.5-s peak was
observed at a position that was only  4A ˚ from the Cb
atom of the methionine residue of the MR solution. The
position of the Se atom (fractional coordinates 0.77428,
0.63843, 0.40618) was conﬁrmed by SHELXD (57). The
ﬁrst crude experimental phases were calculated and subse-
quently reﬁned using the heavy atom position by single-
wavelength anomalous dispersion (SAD) method as
implemented in SHARP (58). This was followed by 120
cycles of solvent ﬂattening from 5.0 to 2.2A ˚ in
SOLOMON (59). The map was drastically improved
using a solvent mask based on the MR solution for the
last 80 cycles of solvent ﬂattening and phase extension.
The structure factors and phases were used as input to
ARP/wARP (60) for automated model building. The
ﬁnal model containing 139 protein residues, 48 water
molecules and one Mg atom was built using iterative
cycles of real space reﬁnement in COOT (61), simulated
annealing/restrained reﬁnement in PHENIX (62) and
restrained reﬁnement in REFMAC (63) against a high-
energy remote dataset collected to 2.20A ˚ at
 =0.95373A ˚ on the same crystal.
Coordinates
The coordinates of the PFV IN CCD have been deposited
in the Protein Data Bank (accession code 3DLR).
RESULTS
Recombinant PFV INis competent forconcerted integration
in vitro
In the context of viral replication, PFV IN is released from
the 1143-residue POL precursor by site-speciﬁc proteolysis
between Asn-751 and Cys-752 (cleavage site:
748YVVN#CNTK
755) (64). Based on earlier work of
Flu ¨ gel and Pahl (65,66), our expression construct for pro-
duction of enzymatically-competent IN was comprised of
PFV POL residues 773–1143, including 40 residues pre-
ceding the conserved HHCC motif. This protein, referred
to as PFV IN, was used in most experiments described in
this work. Both full-length PFV IN and IN were remark-
ably soluble under relatively low ionic strength conditions.
In stark contrast to most retroviral INs, these proteins
could be concentrated to over 10mg/ml in solutions con-
taining just 200mM NaCl in the absence of detergents.
Truncating PFV IN to the start of the predicted a-helical
Zn-binding domain, by removing 30 amino-terminal resi-
dues, severely impaired protein solubility (data not
shown). Concordantly, a similar deletion has been pre-
viously shown to aﬀect enzymatic activity of PFV IN
(66). Based on elution from calibrated gel ﬁltration col-
umns, IN as well as full-length PFV IN behaved as
monodisperse monomeric species (data not shown).
Using supercoiled target DNA in combination with
short mimics of viral cDNA ends (referred to as donor
DNA substrates) permits discrimination between half-
site and concerted integration events (24,25). Concerted
integration of pairs of donor DNA molecules results in
a gapped linear product, while half-site integration pro-
duces tailed open circular DNA species (Figure 1A); both
types of products can be conveniently separated in agarose
gels. Earlier studies suggested that donor DNA molecules
of several hundred base pairs are required to observe con-
certed HIV-1 integration (24,25). Therefore, we initially
tested relatively long (120 or 420bp) donor DNA sub-
strates carrying the natural blunt foamy virus U5 terminal
sequence. Incubation of the 120-bp or 420-bp donor
DNAs with 1.5mM PFV IN in the presence of
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tion of distinct product bands migrating at  3200bp and
3800bp, respectively (Figure 1B, lanes 2 and 3). These
migration positions were consistent with concerted inte-
gration of pairs of 120- and 420-bp donor DNA molecules
into the 2912-bp target plasmid. Also apparent were less
prominent products migrating above the open circular
form of target DNA, which correspond to half site reaction
products. Importantly, no products were formed when
donor DNA was omitted from the reaction (lane 1),
Figure 1. Strand transfer activity of recombinant PFV IN. (A) Schematic of strand transfer reactions using circular DNA target. Concerted
integration results in a gapped linear product, and the half-site process yields tailed relaxed circles. (B) Concerted integration activity of PFV
IN in vitro. The enzyme (1.5mM) was incubated with supercoiled pGEM target DNA in the absence (lane 1) or presence of 100nM donor DNA
(lanes 2–5). Blunt DNA fragments of varying lengths mimicking the U5 PFV cDNA terminus served as donors: 120-bp (lane 2), 420-bp (lane 3), an
equimolar mixture of 120-bp and 420-bp donors (50nM each, lane 4), or a 32-bp oligonucleotide (lane 5). Reaction products separated in 1.5%
agarose gels were detected with ethidium bromide. Migration positions of concerted and half-site reaction products, open circular (o.c.) and super-
coiled (s.c.) pGEM target DNA forms, donor DNA and a DNA size ladder are indicated. (C) PFV IN strand transfer activity in the presence of
0–2.5mM blunt 32-bp donor DNA (lanes 2–10, as indicated). IN was omitted in lane 1. Here and on the remaining panels, the star indicates the
migration position of the concerted integration product. (D) Time course of PFV IN strand transfer reactions in the presence of preprocessed (lanes
1–9) and blunt (lanes 10–18) 32-bp donor DNA. IN was omitted in lanes 1 and 10. (E) Comparison of strand transfer activities of full-length PFV IN
and IN. Supercoiled pGEM target DNA was incubated with 0.38–3mMI N  (lanes 2–5) or full-length PFV IN (lanes 6–9) in the absence (lanes 2
and 6) or presence (lanes 3–5, 7–9) of preprocessed 32-bp donor substrate; IN was omitted in lane 1. (F) Eﬀect of donor DNA length. Strand transfer
reactions using PFV IN and preprocessed donors of 32–14bp, as indicated atop the gel. The enzyme was omitted in lane 1 and donor DNA was
omitted in lane 2.
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was free of contaminating endonuclease activity. When
both types of donor DNA substrates were present in the
same reaction, three product bands migrating at  3200,
3500 and 3800bp were observed (Figure 1B, lane 4). This
result conﬁrmed that a pair of donor DNA molecules was
utilized in formation of the main product. Surprisingly,
eﬃciency of this reaction was not drastically reduced
when a blunt 32-bp donor DNA was used (lane 5), suggest-
ing that PFV IN is able to eﬃciently synapse shorter
donor DNA molecules.
In the course of optimizing reaction conditions, we
observed that increasing the concentration of input
donor DNA greatly augmented the yields of concerted
PFV DNA integration (Figure 1C, lanes 3–10). Of note,
accumulation of the product takes place at the expense of
the supercoiled target, which becomes limiting in the reac-
tion. Concerted integration into the linear product accord-
ingly gives rise to background DNA smears (Figure 1C,
lanes 9 and 10). Using linear target DNA in the reaction
reproduced the expected smear, which was dependent
on the presence of both enzyme and donor DNA
(Supplementary Figure S1A). Subsequent experiments
were performed at the donor:enzyme ratio of 1:2
(0.75mM donor DNA and 1.5mM IN).
Although pre-processed HIV-1 donor DNA is a better
substrate for half-site strand transfer, it was noted that the
eﬃciency of concerted integration was higher when blunt
donor DNA was used (25). In contrast, the PFV enzyme
was able to promote the concerted integration of prepro-
cessed 32-bp donor DNA at least as eﬃciently as the blunt
version (Figure 1D). Notable was  15–30-min delay in
accumulation of products in the reaction with the blunt
donor (compare lanes 3 and 13), consistent with the
requirement for 30-processing of the blunt DNA prior to
strand transfer. Therefore, at least under the reaction con-
ditions used, the concerted strand transfer activity of PFV
IN is not functionally coupled to 30-processing.
Importantly, these observations could be readily extended
to full-length PFV IN, which displayed similar levels of
strand transfer activity when presented with pre-processed
oligonucleotide donor DNA (Figure 1E and data not
shown). Further optimization of the reaction conditions
using PFV IN revealed relatively narrow ionic strength
(110–125mM NaCl; Supplementary Figure S1B) and
broad pH (pH 6–7.5; Supplementary Figure S1C)
optima; strand transfer was abolished when NaCl concen-
tration exceeded 160mM (Supplementary Figure S1B).
The input concentrations of both enzyme and donor
DNA could be reduced to 320 and 80nM, respectively,
by supplementing reactions with DMSO and/or the
crowding agent polyethelene glycol (PEG) (Supplemen-
tary Figure S1D). To determine the minimal length of
donor DNA required for concerted strand transfer
in vitro, we tested a range of preprocessed oligonucleotide
molecules. Strikingly, the substrate could be truncated to
just 16bp without appreciable reduction in PFV IN
strand transfer activity (Figure 1F and data not shown).
Further truncations resulted in a sharp reduction of enzy-
matic activity (Figure 1F, lanes 11 and 12).
Sequence analysis ofthe concertedintegration products
PFV integration results in 4-bp duplication of the target
DNA sequence (5). The duplication size sets an important
constraint on IN–donor complex assembly: the pair of
strand transfer events must target two phosphodiester
bonds at a particular distance ( 17A ˚ in B form DNA)
and a speciﬁc relative orientation for a pair of in-line
nucleophilic substitution reactions. To test the ﬁdelity of
PFV IN-mediated strand transfer under optimized
in vitro conditions, we isolated and cloned concerted inte-
gration products from reactions with preprocessed 32-, 21-
and 16-bp donor DNA substrates. The products were
treated with a strand-displacing DNA polymerase to con-
vert them to nongapped double-stranded linear molecules
and ligated to a blunt-ended kanamycin resistance cas-
sette. Upon transformation of competent bacterial cells,
 70% of recovered kanamycin-resistant plasmids had the
expected structure, based on restriction analysis (data not
shown). Sequencing of individual clones revealed that over
80% of integration products contained pairs of donor
DNA molecules integrated at various positions within
pGEM with the expected 4-bp duplication of the target
DNA sequence (Figure 2A). A minority of integration
products showed 3-bp duplications, large duplications
(>8bp) or deletions. Alignment of all U5-target DNA
junctions recovered in our experiments (n=168) revealed
weak biases toward target DNA sequence (Figure 2B). In
particular, PFV IN appears refractory to insert donor
DNA next to a deoxythymidine (position 0, Figure 2B).
Since the majority of recovered integration events were
concerted, deoxythymidine is also suppressed in the com-
plementary strand at position +3 (Figure 2B). Overall,
the pattern appears similar to the sequence bias observed
in vivo (Supplementary Figure S2A). The overall higher
GC content of the target plasmid used in our experiments
( 50%) compared to that of the human genome ( 41%)
likely accounts for the quantitative diﬀerences between the
two. Indeed, alignment of a subset of in vivo integration
sites (n=440) with the local GC content between 47 and
53% more closely reproduced the in vitro bias for posi-
tions up to +5 (compare Figures 2B and S2B).
PFV INis sensitive toHIV INstrand transfer inhibitors
Sequence alignments highlight only  15% overall amino
acid identity between PFV and HIV-1 INs. Despite being
so divergent, the PFV enzyme was sensitive to HIV IN
strand transfer inhibitors. Thus, the in vitro strand transfer
activity of PFV IN was ablated in the presence of
>200nM of either GS9137 (67) or MK0518 (68)
(Figure 3A). Concordantly, these compounds were able
to suppress transduction of canine D17 cells by a PFV-
based retroviral vector (Figure 3B). The drug concentra-
tions required to inhibit PFV infection by 50% under
these conditions amounted to  800 and 60nM for
GS9137 and MK0518, respectively.
Crystal structure of thePFV INCCD
Encouraged by the unique properties of PFV IN and its
responsiveness to HIV IN inhibitors, and as a ﬁrst step
248 Nucleic Acids Research, 2009, Vol. 37, No. 1toward structural characterization of PFV IN, we deter-
mined the crystal structure of its CCD. A fragment of
PFV IN (residues 109–307; henceforth the residue num-
bering corresponds to full-length IN), spanning the pre-
dicted location of the CCD, readily produced diﬀraction-
quality crystals, and the structure was solved by the
SAD method using a selenomethionine derivative and
reﬁned at 2.2A ˚ resolution (Table 1). The crystals con-
tained one protein chain per asymmetric unit that
formed a dimer with a symmetry-related molecule; a
total of  2000 A ˚ 2 solvent accessible area is buried in the
dimer interface. Despite very limited sequence conserva-
tion between PFV, ASV and HIV-1 INs, the overall struc-
ture and topology of their dimeric CCDs are very similar
(Figure 4A–C). The CCD spans residues 123–269 of PFV
IN (from the beginning of b1 to the end of a6). Apart
form a short a-helix comprised of residues 293–304
(shown in gray, Figure 4A), the region C-terminal to the
CCD was poorly ordered and is not present in the ﬁnal
model. Of note, the C-terminal a helix (residues 293–304)
is involved in the formation of crystal contacts with a
symmetry related molecule and displays high anisotropic
B factors, indicating mobility within the crystal. Hence, it
is unclear if its position in the crystal reﬂects that in the
native protein. In retroviral IN structures reported to date
containing both the CCD and the CTD, the interdomain
linker region was in a-helical or coiled conﬁguration, or
was not observed due to disorder (69–71), suggesting
signiﬁcant ﬂexibility.
As predicted based on multiple sequence alignments
(72), the active site of PFV IN contains three acidic resi-
dues Asp-128, Asp-185 and Glu-221, comprising the
D,DX35E motif (Figure 4D). A single hexacoordinated
magnesium ion with four associated water molecules
(W36, W39, W43 and W44) was observed between the
carboxylates of Asp-128 and Asp-185 (Figure 4D);
the Mg-O distances (1.89–2.45A ˚ ) and O-Mg-O angles
(80–1008) observed in the structure conﬁrm near-
octahedral coordination, expected for the metal ion. As
in ASV and HIV-1 CCDs (12,14), a network of hydrogen
bonds stabilizes the Asp-128 and -185 side-chain rotamers
and the positions of the associated water molecules.
Mutation of PFV IN active site residues Asp-185
(5,72–74) and Glu-221 (72) have been shown to abolish
viral infectivity, retrotransposition and/or the enzymatic
activity of the recombinant protein. Our crystal structure
also explains the phenotype of a more subtle mutation,
I130T, which was shown to severely impair PFV IN func-
tion (5,73). Ile-130 is a largely buried residue that,
via hydrophobic contacts, supports the side chain of
Lys-228, which projects into the active site. Substitution
of Ile-130 for a smaller Thr residue can be predicted to
destabilize the conformation of Lys-228 and thus directly
aﬀect the environment within the active site.
Superposition of the PFV, HIV and ASV structures
revealed the most conserved elements of the retroviral
IN active site, including the location of the Mg
2+
cation, the side chain orientations of the catalytic aspar-
tates 128 and 185 (structurally equivalent to HIV-1 IN
Asp-64 and Asp-116, respectively) and the side chains of
highly conserved Phe-190 (Phe-121 in HIV-1 IN), as well
as those of Ser-184 (Thr-115 in HIV-1 IN) and Tyr-129
(Cys-65 in HIV-1 IN) (Figure 4E). The side chain of
Glu-221, located in the beginning of a4, was only partially
ordered, and clear electron density could not be observed
beyond its Cb atom.
DISCUSSION
Preliminary comparative studies in our laboratory includ-
ing a panel of divergent INs from several retroviral genera
(26) identiﬁed PFV IN as a highly soluble protein. PFV IN
has been previously shown to be capable of 30-processing
and half-site strand transfer in vitro (65,66). The current
study was designed to extend these prior observations and
Figure 2. Sequence analysis of concerted integration products. (A)
Histograms of duplication size distributions in cloned concerted inte-
gration products from reactions mediated by PFV IN utilizing pre-
processed 32-bp (black bars), 24-bp (light gray), or 16-bp (dark gray)
donor DNA substrates. (B) A sequence logo representing nucleotide
base frequencies at PFV integration sites. Target DNA sequences
(n=168) as joined to the reactive strand of donor DNA (from all 84
analyzed clones) were used in the alignment. Black arrowhead indicates
the nucleotide joined to donor DNA (position 0 of the alignment); gray
arrowhead indicates the insertion position of the second donor mole-
cule into the complementary strand (position +3). The height of each
logo is proportional to the frequency of the corresponding nucleotide
within the alignment, while the height of each stack of logos reﬂects the
level of conservation at each position. The ﬁgure was created using
WebLogo (83).
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studies. Here, we demonstrated that this enzyme is highly
proﬁcient at concerted integration in vitro in the absence
of protein or artiﬁcial co-factors. Furthermore, we showed
that PFV IN is capable of utilizing preprocessed oligonu-
cleotide donor DNA substrates as short as 16bp to carry
out almost exclusive concerted strand transfer in vitro,
under physiological conditions. This is in a sharp contrast
to HIV-1 IN that requires unprocessed donor DNA mole-
cules of several hundred base pair and the presence of
DMSO and/or PEG for optimal concerted integration
in vitro (24,25). In fact, in the absence of DMSO, PEG,
and protein co-factors, HIV-1 IN does not display signiﬁ-
cant strand activity (26,75). The lack of functional cou-
pling of 30-processing and concerted integration in the
PFV system may have a functional signiﬁcance. Unlike
in Lentivirus, where both viral cDNA ends are processed
prior to integration, only one cDNA end (U5) is processed
in Spumavirus (5,6). Our ﬁndings are in excellent agree-
ment with and signiﬁcantly extend the results of Delelis
et al. (76) who observed a speciﬁc interaction of PFV IN
with short DNA molecules and reported 30-processing
activity with oligonucleotide substrates as short as 15bp.
Mounting experimental evidence indicates that con-
certed integration is carried out by a tetrameric form of
retroviral IN (77,78). While HIV-1 IN exists in a tetramer-
dimer equilibrium, with the tetrameric form predominat-
ing at concentrations as low as 0.2mM, its PFV counter-
part is mostly monomeric at concentrations below 30 mM
(76). In our hands, size exclusion chromatography failed
to reveal multimeric forms of PFV IN (data not shown).
Surprisingly, it is the latter enzyme that is highly proﬁcient
in concerted integration in vitro, while the former, even
under most optimized conditions, invariably generates
Figure 3. PFV IN is sensitive to HIV IN strand transfer inhibitors. (A) Inhibition of the in vitro strand transfer activity by GS9137 and MK0518.
Preprocessed 32-bp donor DNA substrate was incubated with PFV IN and supercoiled target DNA in the presence (lanes 1–5 and 7–11) or absence
(lanes 6 and 12) of inhibitors. Final drug concentrations were 0.008 mM (lanes 1 and 7), 0.04 mM (lanes 2 and 8), 0.2 mM (lanes 3 and 9), 1 mM (lanes
4 and 10) and 5 mM (lanes 5 and 11). DMSO was present in all reactions at a ﬁnal concentration of 1%. (B) Infection of D17 cells by PFV-based
retroviral vector in the presence of strand transfer inhibitors MK0518 (black line and circles) or GS9137 (gray line and diamonds). Infectivity in the
absence of inhibitors was set to 100%. The dotted gray line represents 50% inhibition.
Table 1. Summary of crystallographic statistics
Data collection
Dataset High remote Peak
Wavelength (A ˚ ) 0.95373 0.97837
Resolution range (A ˚ ) 42.26–2.20 (2.32–2.20)45.00–2.20 (2.32–2.20)
Rsym
a 0.105 (0.681) 0.14 (0.932)
Rpim
a 0.037 (0.233) 0.031 (0.201)
Multiplicity
a 8.9 (9.3) 21.3 (22.2)
I/s
a 17.4 (3.4) 24.9 (4.9)
Completeness (%)
a 99.5 (99.3) 99.7 (99.6)
Reﬁnement
Resolution (A ˚ ) 42.26–2.20
Reﬂections work set 9540
Reﬂections test set 1042
R factor (%) 20.97
Rfree (%) 25.94
No. protein atoms 1241
No. water molecules 48
R.m.s. bonds (A ˚ ) 0.010
R.m.s. angles (8) 1.12
Ramachandran plot (%)
Most favored 93.1
Favored 6.1
Allowed 0.8
Disallowed 0
aData in parentheses represent highest resolution shell.
250 Nucleic Acids Research, 2009, Vol. 37, No. 1considerable amounts of half-site products. Interestingly,
the eﬃciency of HIV-1 concerted integration negatively
correlates with the enzyme concentration, and an opti-
mum of 5–15nM was highlighted by some investigators
(24,79). These observations suggest that a pre-assembled
tetramer of IN may not be a precursor for the active
synaptic complex, and that the enzyme must exist in a
lower multimeric form before interacting with its donor
DNA substrate. As one consequence, less prone to multi-
merize, PFV IN aﬀords studies of the concerted retroviral
integration process at higher IN and donor DNA inputs,
allowing visualization of the concerted products without
resorting to radioactive labeling (Figure 1). Even more
importantly, these properties of PFV IN will be extremely
helpful in future structural studies of the retroviral synap-
tic complex. Although PFV IN is predominantly mono-
meric at concentrations used in our assays, the interaction
with DNA likely enhances its propensity to accrue into a
functional protomer. Indeed, multimers of PFV IN have
been observed in the DNA bound form (76)
Despite possessing a very low level of sequence similar-
ity to HIV INs, the PFV enzyme is sensitive to the HIV
IN strand transfer inhibitors MK0518 and GS9137
(Figure 3A). Moreover, the compounds suppressed
Figure 4. Crystal structure of the PFV IN CCD. (A) Stereo view of the PFV CCD structure. Secondary structure elements are color-coded: light blue
for a-helices, magenta for b-strands, and orange for loops; the C-terminal a-helix comprised of residues 293–304 is painted gray. The catalytic site
residues Asp-128, Asp-185 and Glu-221 are shown as red sticks. Gray spheres are Mg atoms. (B) Structures of the HIV-1 and ASV IN CCDs (PDB
accession codes 1bl3 and 1vsd, respectively) (C) Structure-based amino acid sequence alignment of PFV, HIV-1, and RSV IN CCDs. Secondary
structure elements (a, alpha helix; b, beta strand; Z,3 10 helix) are shown above the alignment. Residue numbering corresponds to the full-length PFV
IN. Residues conserved across the alignment are shown in bold and highlighted in yellow and those of the catalytic D,DX35E motif in red. (D) Stereo
view of the PFV IN active site. Protein structure is shown as sticks; the Mg atom and the associated water molecules are gray and red spheres,
respectively. Residues discussed in the text are labeled. (E) Superposition of the PFV, HIV-1 and ASV IN active sites. Carbon and Mg atoms
(spheres) are colored according to the viral species: PFV, green; HIV-1, blue; ASV, magenta. Residue numbering corresponds to HIV-1 IN. (A), (B),
(D) and (E) were created with PyMOL (DeLano Scientiﬁc, http://www.pymol.org), and (C) with ESPript (84).
Nucleic Acids Research,2009, Vol. 37,No. 1 251infectivity of a PFV-based vector at sub-mM concentra-
tions (Figure 3B), albeit their eﬀective concentrations
were respectively  10- and 1000-fold higher than those
required to inhibit HIV-1 to a similar extent (80).
Comparison of the PFV IN CCD structure reported
here with the available HIV-1 and ASV IN CCD struc-
tures (7,13,56) illuminated key features of the IN active
site conserved among retroviral genera, including confor-
mations of several side chains, and the location of the Mg
atom coordinated by the Asp residues of the D,DX35E
motif (Figure 4E). Our results strongly argue that these
invariant features of the active site are involved in strand
transfer inhibitor binding. Concordantly, mutations at
HIV-1 IN positions 66 and 121 have been implicated in
drug resistance (81). However, it is important to note that
the complete arrangement of the retroviral IN active site
will only emerge in the context of an IN–DNA complex. It
is well established that the enzymes of the RNaseH
superfamily, which includes retroviral INs, utilize a pair
of divalent metal cations during catalysis (8,15). Similar to
the reported structures of HIV-1 and ASV IN CCDs in
their Mg
2+-bound forms (12–14), our PFV IN CCD
structure contains a single Mg
2+ cation coordinated by
the Asp residues of the D,DX35E motif. Coordination of
the other Mg atom is expected to involve the third cata-
lytic carboxylate (Glu-221 in PFV IN and Glu-152 in
HIV-1 IN) as well as ligands donated by a bound DNA
substrate (10,15).
All retroviral genera display distinct preferences toward
genomic DNA features that aﬀect their integration fre-
quencies (27). It is very tempting to speculate that as in
the case of Lentivirus (43–45), it is the interaction between
INs and their cognate chromosomal proteins that deter-
mine the observed site distributions. In HIV-1 IN, CCD
helices a3, a4 and a5 comprise the principal recognition
site for the Lentivirus-speciﬁc host factor LEDGF/p75
(40). The organization of the analogous site in the PFV
IN CCD structure (Figure 5A) is quite divergent from
those of HIV and ASV IN CCDs (Figure 5B and C).
The diﬀerences include relative packing of the helices,
the orientation of the loop connecting a4 and a5 as well
as amino acid composition. Overall, the putative host
factor binding face of PFV IN is less hydrophobic in
content than those of HIV-1 or ASV INs. However, it
remains to be determined whether Spumavirus utilizes an
IN-binding host factor to help determine the frequency of
integration, or, as recently proposed, relies on the ability
of its Gag protein to interact with core histones (82).
HIV IN has been studied since the late 1980s, and
despite its importance as a target for antiretroviral drug
development and enduring eﬀorts in leading laboratories,
the structure of the full-length protein either alone or in
complex with viral DNA remains elusive. With the devel-
opment of clinically useful HIV IN inhibitors (67,68), the
lack of structural data is even more daunting today.
Structural information is urgently needed to ﬁll out miss-
ing details of active site geometry and IN domain interac-
tions during integration, as well as for the design of the
next generation of drugs and for understanding the
mechanisms of drug resistance. Exploration of INs from
divergent retroviruses will illuminate both conserved and
unique features of these proteins and will aid in elucidat-
ing the principal architecture of the retroviral preintegra-
tion complex. Our results as well as the complementary
ﬁndings of others (76) strongly argue that PFV IN pre-
sents a highly relevant and elegant model for further struc-
tural studies.
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